A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression

Biological Psychiatry

Volumn 74, Issue 4, 2013, Pages 257-264

  Zarate Jr , Carlos A ^a   Mathews, Daniel ^a   Ibrahim, Lobna ^a   Chaves, Jose Franco ^a   Marquardt, Craig ^a   Ukoh, Immaculata ^a   Jolkovsky, Libby ^a   Brutsche, Nancy E ^a   Smith, Mark A ^b   Luckenbaugh, David A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Antidepressant; depression; glutamate; low trapping NMDA; rapid acting; treatment resistant

Indexed keywords

AZD 6765; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAM; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VITAL SIGN;

ANTIDEPRESSANT; DEPRESSION; GLUTAMATE; LOW-TRAPPING NMDA; RAPID-ACTING; TREATMENT-RESISTANT;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENETHYLAMINES; PYRIDINES; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84880829258     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2012.10.019     Document Type: Article

References (46)

1. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, and D.S. Charney Antidepressant effects of ketamine in depressed patients Biol Psychiatry 47 2000 351 354
2. N. Diazgranados, L. Ibrahim, N.E. Brutsche, A. Newberg, P. Kronstein, and S. Khalife A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression Arch Gen Psychiatry 67 2010 793 802
3. C.A. Zarate Jr, N.E. Brutsche, L. Ibrahim, J. Franco-Chaves, N. Diazgranados, and A. Cravchik Replication of ketamine's antidepressant efficacy in bipolar depression: A randomized controlled add-on trial Biol Psychiatry 71 2012 939 946
4. G.W. Valentine, G.F. Mason, R. Gomez, M. Fasula, J. Watzl, and B. Pittman The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS Psychiatry Res 191 2011 122 127
5. M. aan het Rot, K.A. Collins, J.W. Murrough, A.M. Perez, D.L. Reich, and D.S. Charney Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression Biol Psychiatry 67 2010 139 145
6. R. Machado-Vieira, G. Salvadore, D.A. Luckenbaugh, H.K. Manji, and C.A. Zarate Jr Rapid onset of antidepressant action: A new paradigm in the research and treatment of major depressive disorder J Clin Psychiatry 69 2008 946 958
7. T.R. Insel, and P.S. Wang The STAR*D trial: Revealing the need for better treatments Psychiatr Serv 60 2009 1466 1467
8. M. aan het Rot, C.A. Zarate Jr, D.S. Charney, and S.J. Mathew Ketamine for depression: Where do we go from here? Biol Psychiatry 72 2012 537 547
9. P. Skolnick, P. Popik, and R. Trullas Glutamate-based antidepressants: 20 years on Trends Pharmacol Sci 30 2009 563 569
10. A.M. Feyissa, A. Chandran, C.A. Stockmeier, and B. Karolewicz Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression Prog Neuropsychopharmacol Biol Psychiatry 33 2009 70 75
11. S. Taniguchi, T. Nakazawa, A. Tanimura, Y. Kiyama, T. Tezuka, and A.M. Watabe Involvement of NMDAR2A tyrosine phosphorylation in depression-related behaviour EMBO J 28 2009 3717 3729
12. S. Maeng, C.A. Zarate Jr, J. Du, R.J. Schloesser, J. McCammon, and G. Chen Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors Biol Psychiatry 63 2008 349 352
13. N. Li, B. Lee, R.J. Liu, M. Banasr, J.M. Dwyer, and M. Iwata mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists Science 329 2010 959 964
14. S.H. Preskorn, B. Baker, S. Kolluri, F.S. Menniti, M. Krams, and J.W. Landen An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder J Clin Psychopharmacol 28 2008 631 637
15. L. Ibrahim, N. Diazgranados, L. Jolkovsky, N. Brutsche, D.A. Luckenbaugh, and W.J. Herring A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder J Clin Psychopharmacol 32 2012 551 557
16. G.A. Mealing, T.H. Lanthorn, C.L. Murray, D.L. Small, and P. Morley Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block J Pharmacol Exp Ther 288 1999 204 210
17. M.J. Ginski, and J.M. Witkin Sensitive and rapid behavioral differentiation of N-methyl-D-aspartate receptor antagonists Psychopharmacology (Berl) 114 1994 573 582
18. J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, and J.D. Bremner Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch Gen Psychiatry 51 1994 199 214
19. C.G. Parsons, G. Quack, I. Bresink, L. Baran, E. Przegalinski, and W. Kostowski Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo Neuropharmacology 34 1995 1239 1258
20. G.C. Palmer, J.A. Miller, E.F. Cregan, P. Gendron, and J. Peeling Low-affinity NMDA receptor antagonists. The neuroprotective potential of ARL 15896AR Ann N Y Acad Sci 825 1997 220 231
21. D.T. Monaghan, and H. Larsen NR1 and NR2 subunit contributions to N-methyl-D-aspartate receptor channel blocker pharmacology J Pharmacol Exp Ther 280 1997 614 620
22. C.A. Zarate Jr Modulating the NMDA receptor complex in developing therapeutics for bipolar disorder and major depressive disorder. Paper presented at: 28th CINP World Congress of Neuropsychopharmacology; June 3-7, 2012; 2012 Stockholm, Sweden
23. K.R. Lees, A.G. Dyker, A. Sharma, G.A. Ford, M.E. Ardron, and D.G. Grosset Tolerability of the low-affinity, use-dependent NMDA antagonist AR-R15896AR in stroke patients: A dose-ranging study Stroke 32 2001 466 472
24. M. Nibuya, S. Morinobu, and R.S. Duman Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments J Neurosci 15 1995 7539 7547
25. R. Hellweg, A. Ziegenhorn, I. Heuser, and M. Deuschle Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment Pharmacopsychiatry 41 2008 66 71
26. L. Ibrahim, W. Duncan, D.A. Luckenbaugh, P. Yuan, R. Machado-Vieira, and C.A. Zarate Jr Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): A pilot study Brain Res Bull 86 2011 129 133
27. M.B. First, R.L. Spitzer, M. Gibbon, and A.R. Williams Structured Clinical Interview for DSM-IV TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P) 2001 New York State Psychiatric Institute, Biometrics Research New York
28. H.A. Sackeim The definition and meaning of treatment-resistant depression J Clin Psychiatry 62 suppl 16 2001 10 17
29. M. Hamilton A rating scale for depression J Neurol Neurosurg Psychiatry 23 1960 56 62
30. A.T. Beck, and A. Beamesderfer Assessment of depression: The depression inventory Mod Probl Pharmacopsychiatry 7 1974 151 169
31. R.C. Aitken Measurement of feelings using visual analogue scales Proc R Soc Med 62 1969 989 993
32. M. Hamilton The assessment of anxiety states by rating Br J Med Psychol 32 1959 50 55
33. A.T. Beck, M. Kovacs, and A. Weissman Assessment of suicidal intention: The Scale for Suicide Ideation J Consult Clin Psychol 47 1979 343 352
34. J.E. Overall, and D.R. Gorham The Brief Psychiatric Rating Scale Psychol Rep 10 1962 799 812
35. J.D. Bremner, J.H. Krystal, F.W. Putnam, S.M. Southwick, C. Marmar, and D.S. Charney Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS) J Trauma Stress 11 1998 125 136
36. R.C. Young, J.T. Biggs, V.E. Ziegler, and D.A. Meyer A rating scale for mania: Reliability, validity and sensitivity Br J Psychiatry 133 1978 429 435
37. C.A. Zarate Jr, J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, and D.A. Luckenbaugh A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression Arch Gen Psychiatry 63 2006 856 864
38. P. Bech, P. Allerup, L.F. Gram, N. Reisby, R. Rosenberg, and O. Jacobsen The Hamilton depression scale. Evaluation of objectivity using logistic models Acta Psychiatr Scand 63 1981 290 299
39. P. Bech, L.F. Gram, E. Dein, O. Jacobsen, J. Vitger, and T.G. Bolwig Quantitative rating of depressive states Acta Psychiatr Scand 51 1975 161 170
40. D. Faries, J. Herrera, J. Rayamajhi, D. DeBrota, M. Demitrack, and W.Z. Potter The responsiveness of the Hamilton Depression Rating Scale J Psychiatr Res 34 2000 3 10
41. C.A. Zarate Jr, N. Brutsche, G. Laje, D.A. Luckenbaugh, S.L. Venkata, and A. Ramamoorthy Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression Biol Psychiatry 72 2012 331 338
42. J. Iga, S. Ueno, K. Yamauchi, S. Numata, S. Tayoshi-Shibuya, and S. Kinouchi Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder Prog Neuropsychopharmacol Biol Psychiatry 31 2007 658 663
43. M. Ventriglia, R. Zanardini, L. Pedrini, A. Placentino, M.G. Nielsen, and M. Gennarelli VEGF serum levels in depressed patients during SSRI antidepressant treatment Prog Neuropsychopharmacol Biol Psychiatry 33 2009 146 149
44. A.E. Autry, M. Adachi, E. Nosyreva, E.S. Na, M.F. Los, and P.F. Cheng NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses Nature 475 2011 91 95
45. E. Beurel, W.I. Yeh, S.M. Michalek, L.E. Harrington, and R.S. Jope Glycogen synthase kinase-3 is an early determinant in the differentiation of pathogenic Th17 cells J Immunol 186 2011 1391 1398
46. A. Anand, D.S. Charney, D.A. Oren, R.M. Berman, X.S. Hu, and A. Cappiello Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists Arch Gen Psychiatry 57 2000 270 276